CytoGenix, Inc. Files US Patent Application for Family of DNA Antimicrobial Agents

Business Wire, July 28, 2005

HOUSTON -- CytoGenix, Inc. (OTCBB:CYGX) announces filing of a patent application with the US Patent and Trademark Office for an invention titled "Nucleotides for Prevention and Treatment of Microbial-Based Pathologies."

Over the past two years, CytoGenix scientists have conducted numerous studies showing that DNA compounds are effective against bacterial pathogens including E. coli and resistant strains of Staphylococcus aureus (MRSA). These studies have led to discoveries of unique compounds and DNA sequences that regulate crucial bacterial proteins.

Life-threatening infections by newly evolving strains of resistant Staph are becoming a significant public health problem. The Centers for Disease Control and Prevention reports, "Staph bacteria are one of the most common causes of skin infection in the United States, and are a common cause of pneumonia and bloodstream infections...as many as 100,000 persons are hospitalized each year with MRSA infections, although only a small proportion of these persons have disease onset occurring in the community."

The nation's annual cost associated with sepsis care is approximately $16.7 billion, and the average length of hospital stay is 19.6 days per patient. The incidence of sepsis is likely to increase because of an aging population and the widespread use of broad-spectrum antibiotics that cause pathogens to mutate and become resistant.

Dr. Malcolm Skolnick, CytoGenix President and CEO, commented, "This patent application includes the results of many months of difficult scientific investigation and covers several discoveries that when combined produce powerful and safe DNA compounds against these very dangerous pathogens."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 42 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.

Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.